BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Image Results

Loading...
Loading...

XIBROM Pages on BioPortfolio:

Biotechnology News XIBROM Search
9 Oct 2009 ... (Nasdaq: ISTA), today announced positive preliminary Phase 3 results from the Company's Xibrom((TM)) (bromfenac ophthalmic solution) 0.09% ...
http://www.bioportfolio.co.uk/XIBROM-news.htm...

BioPortfolio - Xibrom
Xibrom - BioPortfolio - Indepth. ... Companies working in the area of Xibrom from Bioportfolio's Biocorporate database : BioPortfolio Logo. Company Name ...
http://www.bioportfolio.com/indepth/Xibrom.html...

BioPortfolio.com - BioWeb XIBROM BROMFENAC stuard. marsilid ...
Biotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directory.
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?DB=se...

BioPortfolio - Xibrom - InDepth
(http://www.bioportfolio.com/indepth/Xibrom.html) - Regularly Updated. ***. Resources from the NCBI used in this document, NCBI's standard disclaimer ...
http://www.bioportfolio.com/indepth/Xibrom.pdf...

BioPortfolio's Approved Drugs News by Tradename - W to Z
XIBROM ...
http://www.bioportfolio.co.uk/approved_drugs/approved_drug_p...

BioPortfolio Limited The Fastest Growing Biotechnology Companies ...
Xibrom, Istalol, Bepotastine, Ecabet Sodium, Latanoprost and Iganidipine. collaborations with Senju 108. Vitrase commercialization outside the US 108 ...
http://www.bioportfolio.com/cgi-bin/acatalog/2223.html...

BioPortfolio - ISTA Pharmaceuticals - Profile
ISTA has three approved products, Xibrom™ (for the treatment of ocular ... IstalolŪ during Q3 2004, VitraseŪ during Q1 2005 and Xibrom™ during Q2 2005. ...
http://www.bioportfolio.com/biocorporate/24934-ISTA%25252525...

BioPortfolio - ISTA Pharmaceuticals
ISTA has three approved products, Xibrom™ (for the treatment of ocular ... We launched Istalol® during Q3 2004, Vitrase® during Q1 2005 and Xibrom™ during ...
http://www.bioportfolio.com/biocorporate/24934-ISTA_Pharmace...

BioPortfolio News: ISTA Pharmaceuticals, Inc. - ISTA ...
Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5%, Xibrom(TM) ( bromfenac ophthalmic solution) 0.09%, and Istalol® (timolol maleate ophthalmic
...
http://www.bioportfolio.com/news/ISTA-Pharmaceuticals-Highli...

BioPortfolio - Indepth Browse
... Pigmentosum | Xeroderma Pigmentosum Group D Protein | Xeromammography | Xerophthalmia | Xeroradiography | Xerostomia | Xerostomia | Xibrom | Xifaxan ...
http://www.bioportfolio.com/indepth/search/X.htm...

Results from other life science and pharmaceutical sites:

XIBROM (bromfenac sodium) solution [ISTA Pharmaceuticals, Inc ...
Each mL of Xibrom contains 1.035 mg bromfenac sodium equivalent to 0.9 mg bromfenac free acid. Bromfenac sodium is designated chemically as sodium ...
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8783...

FDA Approvals: HepaGam B, Xibrom, Proair HFA
28 Feb 2006 ... The FDA has approved hepatitis B immune globulin [human] injection (HepaGam B), a supplemental indication for bromfenac sodium ophthalmic ...
http://www.medscape.com/viewarticle/524530...

Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ...
OBJECTIVE: To evaluate the efficacy and ocular safety of bromfenac ophthalmic solution 0.09% (Xibrom) for the treatment of postoperative inflammation and ...
http://www.ncbi.nlm.nih.gov/pubmed/17445902...

ISTA says daily Xibrom eye drops met goal in study - Yahoo! Finance
26 Aug 2009 ... IRVINE, Calif. (AP) -- ISTA Pharmaceuticals Inc. on Wednesday reported successful late-stage clinical trial results for Xibrom QD, ...
http://biz.yahoo.com/ap/090826/us_ista_pharma_xibrom.html?.v...

FDA Approvals: Nexium IV, Zofran, Xibrom
7 Apr 2005 ... The FDA has approved an intravenous formulation of esomeprazole magnesium ( Nexium IV), an expanded indication for ondansetron HCl injection ...
http://www.medscape.com/viewarticle/502650...

Global experience with Xibrom (bromfenac ophthalmic solution) 0.09 ...
Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug. ...
http://www.ncbi.nlm.nih.gov/pubmed/17060789...

ISTA Pharmaceuticals Announces Phase III Results for Once-Daily ...
According to a preliminary analysis, integrated results for the two studies demonstrated Xibrom 0.09% QD achieved statistical significance in meeting the
...
http://www.prnewswire.com/news-releases/ista-pharmaceuticals...

Bromfenac - Wikipedia, the free encyclopedia
... discontinued and withdrawn from the US market'). Bromfenac is currently marketed in the US as an ophthalmic solution (brand name: ""Xibrom""). ...
http://en.wikipedia.org/wiki/Bromfenac...

ISTA Pharmaceuticals, Inc. Announces Positive Preliminary Phase 3 ...
Xibrom 0.09% QD achieved statistical significance in the study's primary ... Ltd . ISTA acquired U.S. marketing rights for Xibrom in 2002 and launched the ...
http://www.biospace.com/news_story.aspx?NewsEntityId=154065...

Summary of ISTA PHARMACEUTICALS INC - Yahoo! Finance
5 Nov 2009 ... We announced positive preliminary Phase 3 results from the Xibrom 0.09% QD confirmatory clinical study. Xibrom 0.09% QD achieved statistical ...
http://biz.yahoo.com/e/091105/ista10-q.html...

Google Custom Search

Search
  


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.